SEC Company Response from Revolution Medicines, Inc. (RVMD, RVMDW) (CIK 0001628171) (RVMD) — Feb 10, 2020
Revolution Medicines, Inc. (RVMD, RVMDW) (CIK 0001628171)
Date: Feb. 10, 2020 · CIK: 0001628171 · Accession: 0001193125-20-029739
AI Filing Summary & Sentiment
File numbers found in text: 333-235968
Letter
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, California 94063
February 10, 2020
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention:
Sonia Bednarowski
Dietrich King
Bonnie Baynes
Lisa Vanjoske
Re: Revolution Medicines, Inc. Registration Statement on Form S-1 (Registration No. 333-235968)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-235968) (the “Registration Statement”) of Revolution Medicines, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 12, 2020, or as soon as practicable thereafter, or at such other time as our legal counsel, Latham & Watkins LLP, may request by telephone to the staff of the U.S. Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or John C. Williams at (415) 395-8223.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
Thank you for your assistance in this matter.
Very truly yours,
REVOLUTION MEDICINES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 February 10, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Sonia Bednarowski Dietrich King Bonnie Baynes Lisa Vanjoske Re: Revolution Medicines, Inc. Registration Statement on Form S-1 (Registration No. 333-235968) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-235968) (the “Registration Statement”) of Revolution Medicines, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 12, 2020, or as soon as practicable thereafter, or at such other time as our legal counsel, Latham & Watkins LLP, may request by telephone to the staff of the U.S. Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or John C. Williams at (415) 395-8223. Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. Thank you for your assistance in this matter. Very truly yours, REVOLUTION MEDICINES, INC. By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer CC: Margaret Horn, Revolution Medicines, Inc. Mark Roeder, Latham & Watkins LLP John C. Williams, Latham & Watkins LLP Alexander White, Latham & Watkins LLP Alan F. Denenberg, Davis Polk & Wardwell LLP